The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
Exploration of and Model Establishment of the Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
China-Japan Friendship Hospital
500 participants
Dec 25, 2024
OBSERVATIONAL
Conditions
Summary
Definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. The recommended dose for definitive radiotherapy is 60-70Gy, and the optimal dose is still uncertain. Residual lesion after radiotherapy is a risk factor for recurrence. High doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. The regression pattern of primary lesions in lung caner after radiotherapy has not been clarified. This study intends to retrospectively collect clinical data of lung cancer patients with definitive radiotherapy, and explore the pattern of tumor regression after radiotherapy. It will help optimize the radiotherapy plan for lung cancer, so as to improve the efficacy and prognosis.
Eligibility
Inclusion Criteria6
- Age ≥18 years old;
- Stage II-III lung cancer with a clear pathological diagnosis report or medical record, not undergoing surgery before radiotherapy;
- The primary lung lesion received definitive radiotherapy (defined as conventional fractionation radiotherapy with dose ≥50Gy, stereotactic radiotherapy with biologically effective dose ≥100Gy);
- The target lesion of the lung receiving radiotherapy can be measured;
- Imaging data can be obtained before and after radiotherapy;
- Complete radiotherapy as planned, or the actual received dose has reached the defined definitive dose.
Exclusion Criteria4
- Before radiotherapy, the primary lesion of the lung had received local treatment such as surgery or ablative treatment;
- The radiotherapy plan was not completed, and the actual dose received did not reach the definitive dose (defined as conventional fractionation radiotherapy with dose \<50Gy, stereotactic radiotherapy with biologically effective dose \<100Gy)；
- Required imaging data cannot be obtained;
- Other conditions considered by the investigator to be inappropriate for enrollment.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06692972